Brain-imaging surrogate markers for detection and prevention of age-related memory loss

Recent evidence points to the importance of neuropathological and cognitive changes preceding Alzheimer’s disease (AD), and clinical trials have begun to focus on preventive treatments designed to slow age-related cognitive decline and delay the onset of AD in people with age-associated memory impairment (AAMI). Studying subjects with few deficits leads to diagnostic heterogeneity and a need for larger samples in order to detect active drug effects. In this report, I review results of recent studies designed to address such issues. Middle-aged and older adults with mild memory complaints were studied using brain imaging and measures of the major known genetic risk for AD, the apolipoprotein E-4 (APOE-4) allele. In a study of positron emission tomography during mental rest, glucose metabolic rates were significantly lower in APOE-4 carriers in brain regions affected by AD. Another study using functional magnetic resonance imaging showed increased brain activation during memory tasks in APOE-4 carriers in similar brain regions. Longitudinal follow-up after 2 yr indicated the potential utility of such brain-imaging measures, combined with genetic-risk information, as surrogate markers in treatment trials for AAMI to prevent further cognitive decline. Current development focuses on novel technologies using positron emission tomography to directly image the neuritic plaques and neurofibrillary tangles of AD in order to provide more specific measures of disease progression in future clinical trials.

[1]  Mark S. Cohen,et al.  Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.

[2]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[3]  D. Galton,et al.  Apolipoprotein E genotyping in Alzheimer's disease. , 1996, Lancet.

[4]  C. Bulpitt,et al.  Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. , 1998, Alzheimer disease and associated disorders.

[5]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[6]  J. Barrio,et al.  1,1-Dicyano-2-[6-(dimethylamino)naphthalen-2-yl]propene (DDNP): A Solvent Polarity and Viscosity Sensitive Fluorophore for Fluorescence Microscopy⊥ , 1996 .

[7]  A Pingsmann,et al.  Sample size and statistical power. , 2000, The Journal of bone and joint surgery. American volume.

[8]  P. Lansbury,et al.  Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. , 1996, Chemistry & biology.

[9]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[11]  Ravi S. Menon,et al.  Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Mayo Clinic,et al.  PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .

[13]  Daniel S. O'Leary,et al.  Sample Size and Statistical Power in [15O]H2O Studies of Human Cognition , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[15]  R. Turner,et al.  Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Pettegrew,et al.  Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe , 1995, Neurobiology of Aging.

[17]  D R Wekstein,et al.  Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. , 1996, JAMA.

[18]  J. Haxby,et al.  Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia , 1993, Neurobiology of Aging.

[19]  G H Glover,et al.  Separate neural bases of two fundamental memory processes in the human medial temporal lobe. , 1997, Science.

[20]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[21]  R. Friedland,et al.  Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  P Pietrini,et al.  Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded "stress test" during PET. , 1996, The American journal of psychiatry.

[23]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[24]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[25]  M J de Leon,et al.  Hippocampal formation size predicts declining memory performance in normal aging , 1996, Neurology.

[26]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[27]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[28]  J L Andersson,et al.  Brain regions associated with episodic retrieval in normal aging and Alzheimer’s disease , 1999, Neurology.

[29]  N. Relkin,et al.  Apolipoprotein E genotyping in Alzheimer's disease , 1996, The Lancet.

[30]  D. Galasko,et al.  Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. , 1995, Annals of neurology.

[31]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Raichle,et al.  Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. , 1986, Proceedings of the National Academy of Sciences of the United States of America.